Publication:
Association of Pre-treatment Sarcopenia with Side Effects and Prognosis in Non-small Cell Lung Cancer Patients Receiving Erlotinib

Simple item page
dc.contributor.authorDEMİRCAN, NAZIM CAN
dc.contributor.authorENGÜR, CEREN ÖZGE
dc.contributor.authorAKIN TELLİ, TUĞBA
dc.contributor.authorBAŞOĞLU TÜYLÜ, TUĞBA
dc.contributor.authorARIKAN, RUKİYE
dc.contributor.authorÖZGÜVEN, SALİH
dc.contributor.authorDANE, FAYSAL
dc.contributor.authorKAYA, HANDAN
dc.contributor.authorÖNEŞ, TUNÇ
dc.contributor.authorYUMUK, PERRAN FULDEN
dc.contributor.authorsDEMİRCAN N. C. , ENGÜR C. Ö. , AKIN TELLİ T., BAŞOĞLU TÜYLÜ T., Arikan R., Yasar A., Celebi A., Alan O., Isik S., ÖZGÜVEN S., et al.
dc.date.accessioned2022-10-10T16:53:57Z
dc.date.available2022-10-10T16:53:57Z
dc.date.issued2022-08-01
dc.description.abstractOBJECTIVE We investigated the relationship of baseline sarcopenia with toxicities, treatment response, and survival in patients who had non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation and received erlotinib.METHODS Computed tomography images from PET/CT scans before erlotinib treatment were retrospectively assessed. Skeletal muscle index, calculated as skeletal muscle area at third lumbar vertebra level/square of height, was used to define sarcopenia with < 52.4 cm2/m2 for males and < 38.5 cm2/m2 for females. Cox hazard models were conducted to determine predictors of survival.RESULTS The study included 30 patients, and 11 (36.7%) were sarcopenic. All-grade and Grade 3 toxicities were more frequent in sarcopenic group, although it was statistically insignificant (81.8% vs. 63.2%, p=0.282 for all-grade, and 18.2% vs. 10.5%, p=0.552 for grade 3). Response rates were 63.6% in sarcopenic and 68.4% in non-sarcopenic patients (p=0.789). Median progression-free survival was 7.9 and 9.2 months in sarcopenic and non-sarcopenic cases, respectively (p=0.561). However, median overall survival (OS) of sarcopenic patients was significantly shorter than non-sarcopenic ones (11.8 vs. 30.2 months, p=0.023), and sarcopenia predicted OS independently in multivariate analysis (Hazard ratio=2.63, p=0.029).CONCLUSION Early recognition, treatment, and prevention of sarcopenia may improve long-term survival in EGFRmutant NSCLC patients treated with first-line erlotinib.
dc.identifier.citationDEMİRCAN N. C. , ENGÜR C. Ö. , AKIN TELLİ T., BAŞOĞLU TÜYLÜ T., Arikan R., Yasar A., Celebi A., Alan O., Isik S., ÖZGÜVEN S., et al., "Association of Pre-treatment Sarcopenia with Side Effects and Prognosis in Non-small Cell Lung Cancer Patients Receiving Erlotinib", TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2022
dc.identifier.doi10.5505/tjo.2022.3547
dc.identifier.issn1300-7467
dc.identifier.urihttps://avesis.marmara.edu.tr/api/publication/2482eef0-b7ee-4316-ab4f-f59b5426bbbe/file
dc.identifier.urihttps://hdl.handle.net/11424/282223
dc.language.isoeng
dc.relation.ispartofTURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectSağlık Bilimleri
dc.subjectMedicine
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectOncology
dc.subjectHealth Sciences
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectONCOLOGY
dc.subjectCLINICAL MEDICINE
dc.subjectClinical Medicine (MED)
dc.subjectEpidermal growth factor receptor
dc.subjecterlotinib
dc.subjectnon-small cell lung cancer
dc.subjectprognosis
dc.subjectsarcopenia
dc.subjectBODY-MASS INDEX
dc.subject1ST-LINE TREATMENT
dc.subjectSOLID TUMORS
dc.subjectOPEN-LABEL
dc.subjectCHEMOTHERAPY
dc.subjectTOXICITY
dc.subjectMULTICENTER
dc.subjectDETERMINANT
dc.subjectPREVALENCE
dc.subjectEpidermal growth factor receptor
dc.subjecterlotinib
dc.subjectnon-small cell lung cancer
dc.subjectprognosis
dc.subjectsarcopenia
dc.titleAssociation of Pre-treatment Sarcopenia with Side Effects and Prognosis in Non-small Cell Lung Cancer Patients Receiving Erlotinib
dc.typearticle
dspace.entity.typePublication
local.avesis.id2482eef0-b7ee-4316-ab4f-f59b5426bbbe
local.indexed.atWOS
relation.isAuthorOfPublication8471e450-fb45-4e21-ab29-49db25acbf9a
relation.isAuthorOfPublication489d2fd1-ea81-4816-a7e9-70e6fdc17f5b
relation.isAuthorOfPublication634579fc-78dd-43c6-b231-31cf08aea852
relation.isAuthorOfPublicationddaeb928-6e68-4414-bd70-00515b6656a6
relation.isAuthorOfPublication22952072-1852-47c4-b1ff-669ac16d2ad6
relation.isAuthorOfPublication38325c3e-4399-4724-947c-39953f47fcae
relation.isAuthorOfPublication059ce50a-8d16-4fc6-a86c-85c9baa19a5c
relation.isAuthorOfPublication0bf301ff-2544-4a5e-b38b-b43084d6c255
relation.isAuthorOfPublication98e10a59-a9b0-4f53-894f-be262c4d54f8
relation.isAuthorOfPublication4e7b3d69-6d73-4c60-89e4-d6fddfddd2aa
relation.isAuthorOfPublication.latestForDiscovery8471e450-fb45-4e21-ab29-49db25acbf9a

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
fff.pdf
Size:
320.43 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs